[go: up one dir, main page]

PE20071104A1 - Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv (dpp-4) - Google Patents

Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv (dpp-4)

Info

Publication number
PE20071104A1
PE20071104A1 PE2007000315A PE2007000315A PE20071104A1 PE 20071104 A1 PE20071104 A1 PE 20071104A1 PE 2007000315 A PE2007000315 A PE 2007000315A PE 2007000315 A PE2007000315 A PE 2007000315A PE 20071104 A1 PE20071104 A1 PE 20071104A1
Authority
PE
Peru
Prior art keywords
dpp
inhibitors
tetrahydro
optionally substituted
aminotetrahydropyrans
Prior art date
Application number
PE2007000315A
Other languages
English (en)
Inventor
Tesfaye Biftu
Ann E Weber
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PE20071104A1 publication Critical patent/PE20071104A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE AMINOTETRAHIDROPIRANOS DE FORMULA (I) DONDE Ar ES FENILO OPCIONALMENTE SUSTITUIDO CON R1, DONDE R1 ES HALOGENO, CN, OH, ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON F, O ALCOXI(C1-C6) OPCIONALMENTE SUSTITUIDO CON F; V ES UN COMPUESTO DE FORMULA (i), (ii), (iii), ENTRE OTROS, DONDE R2 ES H, OH, HALOGENO, CN, ENTRE OTROS; R3a Y R3b SON CADA UNO H O ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO CON F. SON COMPUESTOS PREFERIDOS: SAL CLORHIDRATO DE (2R,3S,5R)-5-(1-METIL-4,6-DIHIDROPIRROLO[3,4-c]PIRAZOL-5(1H)-IL)-2-(2,4,5-TRIFLUOROFENIL)TETRAHIDRO-2H-PIRANO-3-AMINA, SAL CLORHIDRATO DE (2R,3S,5R)-2-(2,5-DIFLUOROFENIL)TETRAHIDRO)-5-(4,6-DIHIDROPIRROLO[3,4-c]PIRAZOL-5(1H)-IL)TETRAHIDRO-2H-PIRANO-3-AMINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA DIPEPTIDIL PEPTIDASA-IV (DPP-4) SIENDO UTILES EN EL TRATAMIENTO DIABETES TIPO 2
PE2007000315A 2006-03-28 2007-03-23 Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv (dpp-4) PE20071104A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78651806P 2006-03-28 2006-03-28
US83812206P 2006-08-16 2006-08-16

Publications (1)

Publication Number Publication Date
PE20071104A1 true PE20071104A1 (es) 2007-12-29

Family

ID=38521359

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000315A PE20071104A1 (es) 2006-03-28 2007-03-23 Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv (dpp-4)

Country Status (22)

Country Link
US (1) US7678905B2 (es)
EP (1) EP2001883B1 (es)
JP (1) JP5229706B2 (es)
KR (1) KR20090005306A (es)
AR (1) AR059984A1 (es)
AT (1) ATE554091T1 (es)
AU (1) AU2007243631B2 (es)
BR (1) BRPI0709141A2 (es)
CA (1) CA2646962C (es)
CR (1) CR10343A (es)
DO (1) DOP2007000051A (es)
EA (1) EA200870380A1 (es)
EC (1) ECSP088765A (es)
GT (1) GT200800184A (es)
MA (1) MA30333B1 (es)
MX (1) MX2008012490A (es)
NO (1) NO20084508L (es)
PE (1) PE20071104A1 (es)
SV (1) SV2008003045A (es)
TN (1) TNSN08367A1 (es)
TW (1) TW200806669A (es)
WO (1) WO2007126745A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007218053B2 (en) 2006-02-15 2010-05-27 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP2019677B1 (en) 2006-05-16 2013-08-14 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP5232160B2 (ja) 2006-11-14 2013-07-10 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしての三環式芳香族複素環化合物
WO2009014676A1 (en) * 2007-07-23 2009-01-29 Merck & Co., Inc. Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2696211C (en) 2007-08-21 2015-05-26 Merck Sharp & Dohme Corp. Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7902376B2 (en) 2008-01-23 2011-03-08 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitor intermediates
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
BR112012004335A8 (pt) * 2009-09-02 2016-06-21 Merck Sharp & Dohme Composto, composição farmacêutica, e, uso do composto.
CA2772188A1 (en) * 2009-09-23 2011-03-31 Pfizer Inc. Gpr 119 modulators
EP2480082A4 (en) 2009-09-25 2014-01-15 Merck Sharp & Dohme SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
WO2011103256A1 (en) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011146358A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8691832B2 (en) 2010-12-06 2014-04-08 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN103987388A (zh) 2011-06-29 2014-08-13 默沙东公司 二肽基肽酶-iv抑制剂的新晶形
US9051329B2 (en) 2011-07-05 2015-06-09 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013122920A1 (en) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP2874622A4 (en) 2012-07-23 2015-12-30 Merck Sharp & Dohme TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
WO2014018355A1 (en) * 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-iv inhibitors
TWI500613B (zh) * 2012-10-17 2015-09-21 Cadila Healthcare Ltd 新穎之雜環化合物
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
CN105085528A (zh) * 2014-05-15 2015-11-25 成都贝斯凯瑞生物科技有限公司 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
MY181641A (en) * 2014-06-17 2020-12-30 Sichuan Haisco Pharmaceutical Co Ltd Amino pyran ring derivative and composition and use thereof
WO2016014324A1 (en) 2014-07-21 2016-01-28 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-iv inhibitors
RU2702644C2 (ru) * 2014-10-31 2019-10-09 Ист Чайна Юниверсити Оф Сайенс Энд Текнолоджи Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение
CN105985357A (zh) * 2015-02-12 2016-10-05 北京赛林泰医药技术有限公司 取代的氨基六元饱和杂脂环类长效dpp-iv抑制剂
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
US10377732B2 (en) 2015-12-03 2019-08-13 F.I.S.—Fabbrica Italiana Sintetici S.p.A. Process for preparing aminotetrahydropyrans
WO2017202357A1 (zh) * 2016-05-25 2017-11-30 四川海思科制药有限公司 一种三氟甲基取代的吡喃衍生物的制备方法
WO2017202365A1 (zh) * 2016-05-25 2017-11-30 四川海思科制药有限公司 一种三氟甲基取代的吡喃衍生物制备方法
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
RS67259B1 (sr) 2019-09-19 2025-10-31 Novo Nordisk Healthcare Ag Kompozicije koje aktiviraju piruvat kinazu r (pkr)
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114961A (en) * 1989-06-08 1992-05-19 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
WO2003002553A2 (en) * 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
JP2007513058A (ja) * 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
EP1761532B1 (en) * 2004-06-21 2013-04-10 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
ATE481969T1 (de) 2004-10-01 2010-10-15 Merck Sharp & Dohme Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
JP4999698B2 (ja) 2004-11-29 2012-08-15 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療または予防用のジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合アミノピペリジン
EP1888066B1 (en) 2005-05-25 2012-01-11 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
ATE549926T1 (de) 2005-08-26 2012-04-15 Merck Sharp & Dohme Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
AU2007218053B2 (en) * 2006-02-15 2010-05-27 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP2019677B1 (en) * 2006-05-16 2013-08-14 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP5232160B2 (ja) * 2006-11-14 2013-07-10 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしての三環式芳香族複素環化合物

Also Published As

Publication number Publication date
BRPI0709141A2 (pt) 2011-06-28
JP5229706B2 (ja) 2013-07-03
WO2007126745A3 (en) 2007-12-21
EP2001883A2 (en) 2008-12-17
TW200806669A (en) 2008-02-01
ATE554091T1 (de) 2012-05-15
KR20090005306A (ko) 2009-01-13
EA200870380A1 (ru) 2009-02-27
AU2007243631B2 (en) 2011-11-24
AR059984A1 (es) 2008-05-14
MX2008012490A (es) 2008-10-10
EP2001883B1 (en) 2012-04-18
SV2008003045A (es) 2009-11-09
NO20084508L (no) 2008-10-27
JP2009531437A (ja) 2009-09-03
GT200800184A (es) 2011-09-05
MA30333B1 (fr) 2009-04-01
WO2007126745A2 (en) 2007-11-08
US7678905B2 (en) 2010-03-16
DOP2007000051A (es) 2007-12-15
ECSP088765A (es) 2008-10-31
CR10343A (es) 2008-10-29
CA2646962C (en) 2011-06-21
TNSN08367A1 (en) 2009-12-29
US20070232676A1 (en) 2007-10-04
CA2646962A1 (en) 2007-11-08
AU2007243631A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
PE20071104A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv (dpp-4)
PE20110222A1 (es) Inhibidores de dipeptidilpeptidasa iv
PE20061354A1 (es) Compuestos 2-amino-4-oxobutil como inhibidores de la dipeptidil peptidas-iv
PE20090511A1 (es) Imidazopiridinonas
PE20091211A1 (es) Derivados de pirazolopirimidina como moduladores de pde9a
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
PE20091712A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
PE20110411A1 (es) Imidazopiridazinacarbonitrilos como inhibidores de quinasa
PE20080893A1 (es) Triazoles biciclicos como moduladores de la proteina cinasa
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
PE20110944A1 (es) DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1
PE20060210A1 (es) 8-[3-amino-piperidin-1-il]-xantinas como inhibidores de dpp-iv
PE20110828A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
PE20140378A1 (es) Compuestos y composiciones como inhibidores de la trk
PE20110297A1 (es) Inhibidores de dpp-4 para la cicatrizacion de heridas
PE20070367A1 (es) Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa
PE20120002A1 (es) Derivados de benceno sustituido con glucopiranosilo como inhibidores de sglt2
UA106054C2 (uk) ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИМІДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ TРK-КІНАЗИ
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20130346A1 (es) Compuestos heterociclicos fusionados
PE20090774A1 (es) Compuestos heterociclicos como moduladores de la enzima dgat1
NZ599815A (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed